BioAnalytiX Named to Forbes Greece "30 Under 30"
Our team has been recognized by Forbes Greece for our innovative contributions to the Healthtech sector, marking a significant milestone in our journey.
We are thrilled to announce that BioAnalytiX has been recognized in the prestigious Forbes Greece "30 Under 30" list for 2026, marking a significant milestone in our journey to revolutionize medical diagnostics through artificial intelligence.
A Recognition of Innovation and Impact
This honor celebrates our team's dedication to transforming healthcare through cutting-edge AI technology. Being named among Greece's most promising young innovators validates our mission to make advanced medical diagnostics accessible and accurate for healthcare professionals worldwide.
Our Journey So Far
Since our founding in March 2024, BioAnalytiX has been at the forefront of developing AI-powered solutions for medical imaging analysis. Our flagship product focuses on brain CT scan analysis, helping radiologists detect anomalies with unprecedented accuracy and speed.
What This Means for Healthcare
This recognition amplifies our commitment to:
- Enhancing diagnostic accuracy through advanced AI algorithms
- Reducing time-to-diagnosis for critical conditions
- Supporting healthcare professionals with intelligent decision-making tools
- Making cutting-edge medical technology accessible to healthcare facilities of all sizes
Looking Forward
This achievement motivates us to push boundaries further. We're continuing to refine our technology, expand our partnerships, and work towards our vision of AI-assisted diagnostics becoming a standard of care in medical institutions globally.